Quantitative Ultrasound at the Phalanges in Monitoring Alendronate Therapy

Ultrasound in Medicine and Biology

Volumn 35, Issue 1, 2009, Pages 8-13

  Guido, Nicolosi Mario ^a   Elia, Cristina ^a   Liuzzo, Chantal Catherine ^a   Mario, Campogrande ^a   de Terlizzi, Francesca ^b   Ruggiero, Grio ^c  

^a Ostetricia e Ginecologia Ospedale S Anna   (Italy)

^b IGEA Biophysics Laboratory   (Italy)

^c Ostetricia e Ginecologia Ospedale S Anna   (Italy)

Author keywords

Bisphosphonates; Osteoporosis; Phalanges; Quantitative Ultrasound

Indexed keywords

ACOUSTIC WAVES;

AMPLITUDE DEPENDENTS; BISPHOSPHONATES; MEAN AGES; OSTEOPOROSIS; PHALANGES; POSTMENOPAUSAL WOMEN; QUANTITATIVE ULTRASOUND; QUANTITATIVE ULTRASOUNDS; SPEED OF SOUNDS; TRANSMISSION TIMES; ULTRASOUND MEASUREMENTS;

ULTRASONICS;

ALENDRONIC ACID; CALCIUM; VITAMIN D;

ADULT; ANTHROPOMETRY; ARTICLE; BODY MASS; BONE DENSITOMETRY; BONE METABOLISM; CLIMACTERIUM; CLINICAL PRACTICE; CONTROLLED STUDY; ECHOGRAPHY; FEMALE; FOLLOW UP; HUMAN; INFORMED CONSENT; MAJOR CLINICAL STUDY; OSTEOPOROSIS; OUTCOME ASSESSMENT; PATIENT SELECTION; PHALANX; POSTMENOPAUSE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; ALENDRONATE; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALIBRATION; CASE-CONTROL STUDIES; FEMALE; FINGER PHALANGES; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; TREATMENT OUTCOME;

EID: 57249095843     PISSN: 03015629     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ultrasmedbio.2008.07.007     Document Type: Article

References (22)

1. Adami S., Isaia G., Luisetto G., Minisola S., Sinigaglia L., Gentilella R., Agnusdei D., Iori N., Nuti R., and ICARO Study Group. Fracture incidence and characterization in patients on osteoporosis treatment: The ICARO study. J Bone Miner Res 21 (2006) 1565-1570
2. Agostinelli D., and de Terlizzi F. QUS in monitoring aloxifene and estrogen-progestogens: A 4-year longitudinal study. Ultrasound Med Biol 33 (2007) 1184-1190
3. Anonymous. Consensus Development Conference: Prophylaxis and Treatment of Osteoporosis. Am J Med 1993;94:646-650.
4. Black D.M., Cummings S.R., Karpf D.B., Cauley J.A., Thompson D.E., Nevitt M.C., Bauer D.C., Genant H.K., Haskell W.L., Marcus R., Ott S.M., Torner J.C., Quandt S.A., Reiss T.F., and Ensrud K.E. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348 (1996) 1535-1541
5. Cavani F., Fini M., de Terlizzi F., Cadossi M., Ciminelli L., Ortolani S., Cherubini R., De Aloysio D., Giavaresi G., Cadossi R., and Canè V. Effect of trabecular orientation on mechanical resistance and ultrasound propagation in specimens of equine vertebrae. Ultrasound Med Biol 29 (2003) 1777-1785
6. Drake W.M., Brown J.P., Banville C., and Kendler D.L. Use of phalangeal bone mineral density and multi-site speed of sound conduction to monitor therapy with alendronate in postmenopausal women. Osteoporos Int 13 (2002) 249-256
7. Felsenberg D., Alenfeld F., Bock O., Hammermeister C., and Gowan W. Placebo-controlled multicenter study of oral alendronate in postmenopausal osteoporotic women. FOSIT-Study-Group. Fosamax International Trial. Maturitas 31 (1998) 35-44
8. Gluer C.C. Sense and sensitivity: Monitoring skeletal changes by radiological techniques. J Bone Miner Res 14 (1999) 1952-1962
9. Gonnelli S., Cepollaro C., Pondrelli C., Martini S., Rossi S., and Gennari C. Ultrasound parameters in osteoporotic patients treated with salmon calcitonin: A longitudinal study. Osteoporos Int 6 (1996) 303-307
10. Gonnelli S., Cepollaro C., Montagnani A., Martini S., Gennari L., Mangeri M., and Gennari C. Heel ultrasonography in monitoring alendronate therapy: A four-year longitudinal study. Osteoporos Int 13 (2002) 415-421
11. Gonnelli S., and Cepollaro C. The use of ultrasound in the assessment of bone status. J Endocrinol Invest 25 (2002) 389-397
12. Gonnelli S., Martini G., Caffarelli C., Salvadori S., Cadirni A., Montagnani A., and Nuti R. Teriparatide's effects on quantitative ultrasound parameters and bone density in women with established osteoporosis. Osteoporos Int 17 (2006) 1524-1531
13. Ingle B.M., Machado A.B., Pereda C.A., and Eastell R. Monitoring alendronate and oestradiol therapy with quantitative ultrasound and bone mineral density. J Clin Densitom 8 (2005) 278-286
14. Krieg M.A., Jacquet A.F., Bremgartner M., Cuttelod S., Thiebaud D., and Burckhardt P. Effect of supplementation with vitamin D3 and calcium on quantitative ultrasound of bone in elderly institutionalized women: A longitudinal study. Osteoporos Int 9 (1999) 483-488
15. Krieg M.A., Barkmann R., Gonnelli S., Stewart A., Bauer D.C., Del Rio Barquero L., Kaufman J.J., Lorenc R., Miller P.D., Olszynski W.P., Poiana C., Schott A.M., Lewiecki E.M., and Hans D. Quantitative ultrasound in the management of osteoporosis: The 2007 ISCD official positions. J Clin Densitom 11 (2008) 163
16. Mauloni M., Rovati L.C., Cadossi R., de Terlizzi F., Ventura V., and de Aloysio D. Monitoring bone effect of transdermal hormone replacement therapy by ultrasound investigation at the phalanx: A four-year follow-up study. Menopause 7 (2000) 402-412
17. Noteloviz M. Osteoporosis: Screening, prevention and management. Fertil Steril 59 (1993) 707-725
18. Pols H.A., Felsenberg D., Hanley D.A., Stepán J., Muñoz-Torres M., Wilkin T.J., Qin-sheng G., Galich A.M., Vandormael K., Yates A.J., and Stych B. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 9 (1999) 461-468
19. Sakata S., Barkmann R., Lochmuller E.M., Heller M., and Gluer C.C. Assessing bone status beyond bone mineral density: Evaluation of bone geometry and porosity by quantitative ultrasound of human finger phalanges. J Bone Miner Res 19 (2004) 924-930
20. Tucci J.R., Tonino R.P., Emkey R.D., Peverly C.A., Kher U., and Santora A.C. Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med 101 (1996) 488-501
21. Welton A., Hepworth J., Collins N., Ford D., Knott C., Meredith S., Walgrove A., Wilkes H., Vickers M., and Women's International Study of Long Duration Oestrogen after Menopause (WISDOM) team. Decision-making about hormone replacement therapy by women in England and Scotland. Climacteric 7 (2004) 41-49
22. WHO Study Group. Assessment of Fracture Risk and its Application to Screening for Postmenopausal Osteoporosis. WHO Technical Report Series, Geneva, 843, 1994.